A Review on Recent Approaches on Molecular Docking Studies of Novel Compounds Targeting Acetylcholinesterase in Alzheimer Disease.
Stergiani-Chrysovalanti PeitzikaEleni PontikiPublished in: Molecules (Basel, Switzerland) (2023)
Alzheimer's disease (AD), a neurodegenerative brain disorder that affects millions of people worldwide, is characterized by memory loss and cognitive decline. Low levels of acetylcholine and abnormal levels of beta-amyloid, T protein aggregation, inflammation, and oxidative stress, have been associated with AD, and therefore, research has been oriented towards the cholinergic system and primarily on acetylcholinesterase (AChE) inhibitors. In this review, we are focusing on the discovery of AChE inhibitors using computer-based modeling and simulation techniques, covering the recent literature from 2018-2022. More specifically, the review discusses the structures of novel, potent acetylcholinesterase inhibitors and their binding mode to AChE, as well as the physicochemical requirements for the design of potential AChE inhibitors.
Keyphrases
- cognitive decline
- molecular docking
- oxidative stress
- mild cognitive impairment
- systematic review
- small molecule
- high resolution
- dna damage
- binding protein
- working memory
- machine learning
- deep learning
- signaling pathway
- induced apoptosis
- transcription factor
- risk assessment
- protein protein
- climate change
- drug delivery
- human health